2023
A pilot study of volumetric and density tumor analysis of ACC patients treated with vorinostat in a phase II clinical trial
Malarkey M, Toscano A, Bagheri M, Solomon J, Machado L, LoRusso P, Chen A, Folio L, Goncalves P. A pilot study of volumetric and density tumor analysis of ACC patients treated with vorinostat in a phase II clinical trial. Heliyon 2023, 9: e18680. PMID: 37593628, PMCID: PMC10428039, DOI: 10.1016/j.heliyon.2023.e18680.Peer-Reviewed Original ResearchACC patientsClinical trialsTarget lesionsSolid tumorsPhase II clinical trialPilot studyPhase 2 trialResponse Evaluation CriteriaSalivary gland cancerRare salivary gland cancerSystemic therapy efficacyStable diseaseGland cancerLung lesionsComputed tomography (CT) examsCystic carcinomaTherapy responseBlinded observersTomography examsTherapy efficacyLesionsInter-observer variationPatientsAppropriate evaluationTrials
2014
Enzalutamide plus exemestane: A pilot study to assess safety, pharmacokinetics, and effects on circulating estrogens in women with advanced hormone-positive breast cancer.
Schwartzberg L, Yardley D, Elias A, Patel M, Gucalp A, Burris H, Peterson A, Hannah A, Blaney M, Gibbons J, Tudor I, Steinberg J, LoRusso P, Infante J, Hudis C, Traina T. Enzalutamide plus exemestane: A pilot study to assess safety, pharmacokinetics, and effects on circulating estrogens in women with advanced hormone-positive breast cancer. Journal Of Clinical Oncology 2014, 32: 545-545. DOI: 10.1200/jco.2014.32.15_suppl.545.Peer-Reviewed Original Research